TMB-L

News alerts, weekly reports and conference planners

Related biomarkers:

Expression

Others

‹

›

TMB-L	Melanoma	TMB-L	Melanoma	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials trametinib + dabrafenib + PDR001 Sensitive : B	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials trametinib + dabrafenib + PDR001 Sensitive : B
TMB-L	Follicular Lymphoma	TMB-L	Follicular Lymphoma	rituximab Sensitive: B - Late Trials rituximab Sensitive : B	rituximab Sensitive: B - Late Trials rituximab Sensitive : B
TMB-L	Colorectal Cancer	TMB-L	Colorectal Cancer	durvalumab + tremelimumab Sensitive: C3 – Early Trials durvalumab + tremelimumab Sensitive : C3	durvalumab + tremelimumab Sensitive: C3 – Early Trials durvalumab + tremelimumab Sensitive : C3
TMB-L	Adrenal Cortex Carcinoma	TMB-L	Adrenal Cortex Carcinoma	mitotane Sensitive: C3 – Early Trials mitotane Sensitive : C3	mitotane Sensitive: C3 – Early Trials mitotane Sensitive : C3
TMB-L	Malignant Pleural Mesothelioma	TMB-L	Malignant Pleural Mesothelioma	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3
TMB-L	Malignant Pleural Mesothelioma	TMB-L	Malignant Pleural Mesothelioma	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3
TMB-L	Glioblastoma	TMB-L	Glioblastoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
TMB-L	Non Small Cell Lung Cancer	TMB-L	Non Small Cell Lung Cancer	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3
TMB-L	Non Small Cell Lung Cancer	TMB-L	Non Small Cell Lung Cancer	durvalumab + tremelimumab Resistant: C3 – Early Trials durvalumab + tremelimumab Resistant : C3	durvalumab + tremelimumab Resistant: C3 – Early Trials durvalumab + tremelimumab Resistant : C3
TMB-L	Pancreatic Cancer	TMB-L	Pancreatic Cancer	nivolumab + BMS-986227 Sensitive: C3 – Early Trials nivolumab + BMS-986227 Sensitive : C3	nivolumab + BMS-986227 Sensitive: C3 – Early Trials nivolumab + BMS-986227 Sensitive : C3
TMB-L	Lung Cancer	TMB-L	Lung Cancer	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
TMB-L	Gastric Cancer	TMB-L	Gastric Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
TMB-L	Mast Cell Leukemia	TMB-L	Mast Cell Leukemia	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
TMB-L	Diffuse Large B Cell Lymphoma	TMB-L	Diffuse Large B Cell Lymphoma	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
TMB-L	Non Small Cell Lung Cancer	TMB-L	Non Small Cell Lung Cancer	nivolumab + HS-110 Sensitive: C3 – Early Trials nivolumab + HS-110 Sensitive : C3	nivolumab + HS-110 Sensitive: C3 – Early Trials nivolumab + HS-110 Sensitive : C3
TMB-L	Neuroendocrine Tumor	TMB-L	Neuroendocrine Tumor	toripalimab-tpzi Sensitive: C3 – Early Trials toripalimab-tpzi Sensitive : C3	toripalimab-tpzi Sensitive: C3 – Early Trials toripalimab-tpzi Sensitive : C3
TMB-L	Colorectal Cancer	TMB-L	Colorectal Cancer	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
TMB-L	Non Small Cell Lung Cancer	TMB-L	Non Small Cell Lung Cancer	palbociclib + avelumab + axitinib Sensitive: C3 – Early Trials palbociclib + avelumab + axitinib Sensitive : C3	palbociclib + avelumab + axitinib Sensitive: C3 – Early Trials palbociclib + avelumab + axitinib Sensitive : C3
TMB-L	Triple Negative Breast Cancer	TMB-L	Triple Negative Breast Cancer	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3
TMB-L	Lymphoma	TMB-L	Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
TMB-L	Non Small Cell Lung Cancer	TMB-L	Non Small Cell Lung Cancer	avelumab + axitinib Sensitive: C3 – Early Trials avelumab + axitinib Sensitive : C3	avelumab + axitinib Sensitive: C3 – Early Trials avelumab + axitinib Sensitive : C3
TMB-L	Breast Cancer	TMB-L	Breast Cancer	nivolumab + COM701 Sensitive: C3 – Early Trials nivolumab + COM701 Sensitive : C3	nivolumab + COM701 Sensitive: C3 – Early Trials nivolumab + COM701 Sensitive : C3
TMB-L	Triple Negative Breast Cancer	TMB-L	Triple Negative Breast Cancer	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3
TMB-L	Pancreatic Ductal Adenocarcinoma	TMB-L	Pancreatic Ductal Adenocarcinoma	trametinib + Torin1 Sensitive: D – Preclinical trametinib + Torin1 Sensitive : D	trametinib + Torin1 Sensitive: D – Preclinical trametinib + Torin1 Sensitive : D
TMB-L	Gastric Cancer	TMB-L	Gastric Cancer	olaparib Resistant: D – Preclinical olaparib Resistant : D	olaparib Resistant: D – Preclinical olaparib Resistant : D

TMB-L

Associations